4.18 -0.09 (-2.11%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 5.51 | 1-year : | 6.43 |
Resists | First : | 4.72 | Second : | 5.51 |
Pivot price | 4.64 | |||
Supports | First : | 3.44 | Second : | 2.86 |
MAs | MA(5) : | 4.17 | MA(20) : | 4.61 |
MA(100) : | 3.34 | MA(250) : | 2.97 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 15.8 | D(3) : | 12.4 |
RSI | RSI(14): 45.7 | |||
52-week | High : | 5.51 | Low : | 1.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IPSC ] has closed above bottom band by 19.8%. Bollinger Bands are 23.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 4.4 - 4.43 | 4.43 - 4.45 |
Low: | 3.98 - 4.01 | 4.01 - 4.04 |
Close: | 4.13 - 4.18 | 4.18 - 4.22 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Tue, 19 Mar 2024
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewswire
Fri, 15 Mar 2024
Century Therapeutics Inc (IPSC) is lower by -5.53% in a Week, Should You Hold? - InvestorsObserver
Thu, 14 Mar 2024
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 - InvestorPlace
Fri, 08 Mar 2024
Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares - Yahoo Finance
Wed, 06 Mar 2024
Is Century Therapeutics Inc (IPSC) Stock About to Get Hot Wednesday? - InvestorsObserver
Tue, 05 Mar 2024
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer ... - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 65 (M) |
Held by Insiders | 2.636e+007 (%) |
Held by Institutions | 36.4 (%) |
Shares Short | 846 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.1214e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -11 % |
Return on Assets (ttm) | 424.2 % |
Return on Equity (ttm) | -18.5 % |
Qtrly Rev. Growth | 2.23e+006 % |
Gross Profit (p.s.) | -37.39 |
Sales Per Share | -43.14 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -2.3 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -88 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0.1 |
Price to Book value | 0 |
Price to Sales | -0.1 |
Price to Cash Flow | 1.77 |
Dividend | 0 |
Forward Dividend | 1.75e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |